Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort - Scorecard - MDSpire
Advertisement
Systemic Influences Linked to Suboptimal Anatomical Outcomes Following Anti-VEGF Treatment in Diabetic Macular Edema Patients: Insights from a Large Clinical Cohort
Clinical Scorecard: Systemic Influences Linked to Suboptimal Anatomical Outcomes Following Anti-VEGF Treatment in Diabetic Macular Edema Patients: Insights from a Large Clinical Cohort
At a Glance
Category
Detail
Condition
Diabetic Macular Edema (DME)
Key Mechanisms
Chronic hyperglycemia induces microvascular damage, leading to increased vascular permeability and accumulation of fluid in the retina.
Target Population
Patients with Diabetic Macular Edema undergoing anti-VEGF therapy.
Care Setting
Retrospective cohort study analyzing treatment outcomes in a clinical setting.
Key Highlights
41.48% of eyes classified as responders to anti-VEGF treatment.
Significant reduction in central macular thickness (CMT) from baseline to three months.
Baseline CMT, BCVA, LDL-C, fasting blood glucose, and HbA1c are associated with anatomical response.
Systemic metabolic status impacts the effectiveness of anti-VEGF therapy.
Integration of metabolic optimization is crucial in managing DME.
Guideline-Based Recommendations
Diagnosis
Assess central macular thickness and best-corrected visual acuity for DME diagnosis.
Management
Administer intravitreal Conbercept as first-line treatment for DME.
Monitoring & Follow-up
Monitor fasting blood glucose and HbA1c levels to optimize systemic metabolic status.
Risks
Patients with higher baseline HbA1c and fasting glucose may have poorer anatomical responses.
Patient & Prescribing Data
691 patients with DME analyzed in the study.
Conbercept administered monthly for three months showed significant anatomical and visual improvements.
Clinical Best Practices
Incorporate systemic metabolic assessments into treatment planning for DME.
Utilize standardized definitions for treatment response to guide clinical decisions.
This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
